These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 25719997)
1. Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic. Med Lett Drugs Ther; 2015 Mar; 57(1463):31-3. PubMed ID: 25719997 [No Abstract] [Full Text] [Related]
2. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990 [TBL] [Abstract][Full Text] [Related]
3. Ceftolozane-tazobactam: A new-generation cephalosporin. Cluck D; Lewis P; Stayer B; Spivey J; Moorman J Am J Health Syst Pharm; 2015 Dec; 72(24):2135-46. PubMed ID: 26637512 [TBL] [Abstract][Full Text] [Related]
4. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. Kuti JL; Ghazi IM; Quintiliani R; Shore E; Nicolau DP Int J Antimicrob Agents; 2016 Sep; 48(3):342-3. PubMed ID: 27451086 [No Abstract] [Full Text] [Related]
5. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model. Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793 [TBL] [Abstract][Full Text] [Related]
6. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Gentile I; Maraolo AE; Borgia G Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088 [No Abstract] [Full Text] [Related]
7. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination. Sucher AJ; Chahine EB; Cogan P; Fete M Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970 [TBL] [Abstract][Full Text] [Related]
8. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244 [TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections. Bassetti M; Righi E Future Microbiol; 2015; 10(2):151-60. PubMed ID: 25689527 [TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections. Scott LJ Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. Wagenlehner FM; Alidjanov JF Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):959-66. PubMed ID: 27327964 [TBL] [Abstract][Full Text] [Related]
12. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection. Popa C; Mircheva M; Krämer BK; Berghofen A; Krüger B Lancet; 2015 Sep; 386(10000):1241-1242. PubMed ID: 26460657 [No Abstract] [Full Text] [Related]
17. Infection: Ceftolozane-tazobactam gives a new ASPECT to the fight against antimicrobial resistance. Edwards JK Nat Rev Urol; 2015 Jun; 12(6):306. PubMed ID: 25963963 [No Abstract] [Full Text] [Related]
18. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy. Gentile I; Buonomo AR; Maraolo AE; Scotto R; De Zottis F; Di Renzo G; Borgia G J Antimicrob Chemother; 2017 Sep; 72(9):2678-2679. PubMed ID: 28575437 [No Abstract] [Full Text] [Related]
19. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823 [TBL] [Abstract][Full Text] [Related]
20. Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications. Tamma SM; Hsu AJ; Tamma PD Paediatr Drugs; 2016 Feb; 18(1):1-11. PubMed ID: 26645401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]